Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371551 | 1.00 | TSHR (0.50) | TSHRHCRTR2HCRTR1L3MBTL1TBXA2R | |
| SCHEMBL16377614 | 1.00 | TSHR (0.50) | TSHRHCRTR2HCRTR1L3MBTL1TBXA2R | |
| SCHEMBL17548775 | 0.82 | TSHR (0.48) | TSHRHCRTR2HCRTR1KDM1AMAOA | |
| SCHEMBL22479923 | 0.82 | CACNA1G (0.35) | TSHRHCRTR2HCRTR1MAOB | |
| SCHEMBL16652185 | 0.81 | CACNA1G (0.35) | HCRTR2HCRTR1 | |
| SCHEMBL16652186 | 0.81 | CACNA1G (0.35) | HCRTR2HCRTR1 | |
| SCHEMBL1305945 | 0.81 | HCRTR2 (0.42) | TSHRHCRTR2HCRTR1KDM1AMAOB | |
| SCHEMBL7254156 | 0.81 | ESR2 (0.41) | HCRTR2HCRTR1 | |
| SCHEMBL19432763 | 0.81 | CACNA1G (0.35) | HCRTR2HCRTR1 | |
| SCHEMBL1305947 | 0.81 | HCRTR2 (0.42) | TSHRHCRTR2HCRTR1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118814185-A | Use of fluoroborate-mediated electrochemical [3+2] ring-expansion strategy for synthesis of 1, 3-dioxolane and oxazoline derivatives | 南京大学天长新材料与能源技术研发中心 | 2024-10-22 | — | — | CN | claimed |
| CN-116807912-A | Use of volatile components to limit or eliminate perception of malodor | 弗门尼舍有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | claimed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | claimed |
| EP-3713610-A2 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | Firmenich SA (CH) | 2020-09-30 | — | — | EP | claimed |
| CN-111432851-A | Use of volatile ingredients to limit or eliminate perception of malodour | 弗门尼舍有限公司 | 2020-07-17 | — | — | CN | claimed |
| WO-2019101821-A2 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2019-05-31 | — | — | WO | claimed |
| US-20250186646-A1 | Use of Volatile Compositions to Limit or Eliminate Perception of Fecal Malodour | FIRMENICH SA (CH) | 2025-06-12 | — | — | US | disclosed |
| EP-4218837-B1 | VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE PERCEPTION OF FECAL MALODOUR | FIRMENICH & CIE (CH) | 2024-11-27 | — | — | EP | disclosed |
| CN-118814185-A | Use of fluoroborate-mediated electrochemical [3+2] ring-expansion strategy for synthesis of 1, 3-dioxolane and oxazoline derivatives | 南京大学天长新材料与能源技术研发中心 | 2024-10-22 | — | — | CN | disclosed |
| CN-116807912-A | Use of volatile components to limit or eliminate perception of malodor | 弗门尼舍有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | FIRMENICH SA (CH) | 2023-09-05 | — | — | US | disclosed |
| EP-3541435-B1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE PERCEPTION OF FECAL MALODOUR | FIRMENICH & CIE (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-7671219-B2 | Method for manufacturing fullerene derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080139826-A1 | Method For Manufacturing Fullerene Derivatives | RIKEN (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139826-A1 | Method For Manufacturing Fullerene Derivatives | RIKEN (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1767532-A1 | METHOD FOR PRODUCING FULLERENE DERIVATIVE | Riken (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-7176176-B2 | 2-methyl-4-phenyl-1,3-dioxolane | SYMRISE GMBH & CO. KG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20010004457-A1 | 2-methyl-4-pheny1-1,3-dioxolane | SYMRISE GMBH & CO. KG (DE) | 2001-06-21 | — | — | US | disclosed |
| EP-0150398-B1 | METHYLPHENYLDIOXOLANES, THEIR PREPARATION AND USE AS ODORIFEROUS SUBSTANCES AND SMELLING COMPOSITIONS CONTAINING THEM | Henkel Kommanditgesellschaft auf Aktien (DE) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | TAS2R8, TRPA1, TAS2R10 | TSHR 2144/4885HCRTR2 305/4885HCRTR1 325/4885 |
| US-20080139826-A1 | Method For Manufacturing Fullerene Derivatives | RNF168, PPOX, USP9X | TSHR 4397/4885HCRTR2 4361/4885HCRTR1 3643/4885 |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | TSHR 2144/4885HCRTR2 305/4885HCRTR1 325/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | TSHR 2144/4885HCRTR2 305/4885HCRTR1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.